RBOT Quote, Financials, Valuation and Earnings

GlucoTrack has a net margin of -- compared to Vicarious Surgical's net margin of --. Vicarious Surgical's return on equity of -- beat GlucoTrack's return on equity of --.

Vicarious Surgical has a consensus price target of $10.75, signalling upside risk potential of 7.07%. On the other hand GlucoTrack has an analysts' consensus of -- which suggests that it could fall by --. Given that Vicarious Surgical has higher upside potential than GlucoTrack, analysts believe Vicarious Surgical is more attractive than GlucoTrack.

Vicarious Surgical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GlucoTrack has a beta of -0.236, suggesting its less volatile than the S&P 500 by 123.622%.

Vicarious Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GlucoTrack offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vicarious Surgical pays -- of its earnings as a dividend. GlucoTrack pays out -- of its earnings as a dividend.

Vicarious Surgical quarterly revenues are --, which are smaller than GlucoTrack quarterly revenues of --. Vicarious Surgical's net income of -$15.4M is lower than GlucoTrack's net income of -$6.8M. Notably, Vicarious Surgical's price-to-earnings ratio is -- while GlucoTrack's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vicarious Surgical is -- versus 6.90x for GlucoTrack. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -- compared to Vicarious Surgical's net margin of -2201.34%. Vicarious Surgical's return on equity of -- beat VolitionRX's return on equity of --.

Vicarious Surgical has a consensus price target of $10.75, signalling upside risk potential of 7.07%. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 334.72%. Given that VolitionRX has higher upside potential than Vicarious Surgical, analysts believe VolitionRX is more attractive than Vicarious Surgical.

Vicarious Surgical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

Vicarious Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vicarious Surgical pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Vicarious Surgical quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $246.4K. Vicarious Surgical's net income of -$15.4M is lower than VolitionRX's net income of -$5.4M. Notably, Vicarious Surgical's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vicarious Surgical is -- versus 46.61x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -- compared to Vicarious Surgical's net margin of -2828.67%. Vicarious Surgical's return on equity of -- beat Catheter Precision's return on equity of -137.84%.

Vicarious Surgical has a consensus price target of $10.75, signalling upside risk potential of 7.07%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 794.06%. Given that Catheter Precision has higher upside potential than Vicarious Surgical, analysts believe Catheter Precision is more attractive than Vicarious Surgical.

Vicarious Surgical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.724, suggesting its less volatile than the S&P 500 by 172.434%.

Vicarious Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vicarious Surgical pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Vicarious Surgical quarterly revenues are --, which are smaller than Catheter Precision quarterly revenues of $143K. Vicarious Surgical's net income of -$15.4M is lower than Catheter Precision's net income of -$4M. Notably, Vicarious Surgical's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vicarious Surgical is -- versus 2.57x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Vicarious Surgical's net margin of 0.18%. Vicarious Surgical's return on equity of -- beat Xtant Medical Holdings's return on equity of -26.62%.

Vicarious Surgical has a consensus price target of $10.75, signalling upside risk potential of 7.07%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 182.26%. Given that Xtant Medical Holdings has higher upside potential than Vicarious Surgical, analysts believe Xtant Medical Holdings is more attractive than Vicarious Surgical.

Vicarious Surgical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

Vicarious Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vicarious Surgical pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Vicarious Surgical quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Vicarious Surgical's net income of -$15.4M is lower than Xtant Medical Holdings's net income of $58K. Notably, Vicarious Surgical's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vicarious Surgical is -- versus 0.69x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.